CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion Pharmaceuticals uses AI in drug development, increasing success rates in lab and animal testing, with upcoming data readouts for five Phase 2 programs. The company is a "TechBio," with ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

AI for drug development is very fashionable in biotech, and for good reason. 23andMe's consumer business could one day provide a bedrock of stability. Recursion Pharmaceutical's research services ...